• Julia Pohl, Ulrike B Hendgen-Cotta, Pia Stock, Peter Luedike, and Tienush Rassaf.
• University Hospital Essen, West German Heart and Vascular Center, Department of Cardiology and Vascular Medicine, Hufelandstr. 55, 45147 Essen, Germany. Electronic address: J.Pohl@uk-essen.de.
• J Crit Care. 2017 Aug 1; 40: 52-57.

PurposeD-dopachrome tautomerase (MIF-2 or DDT) is a member of the macrophage migration inhibitory factor (MIF) superfamily and a close structural homolog to MIF. Circulating MIF-2 has been described to be elevated in patients suffering from sepsis, severe burn injury and after surgery. We sought to evaluate the prognostic value of MIF-2 in critically ill patients.MethodsA total of 72 patients were studied upon admission to the medical intensive care unit (ICU). MIF and MIF-2 levels were assessed and compared to healthy controls. Clinical data, various laboratory parameters and mortality were assessed.ResultsWe found significantly elevated levels of MIF-2 and MIF at admission to the ICU in critically ill patients compared to healthy controls. MIF-2 levels were associated with disease severity as measured by APACHE II scores. MIF-2 levels in ICU patients correlated with biomarkers reflecting organ damage, but were not influenced by acute or chronic kidney disease. Kaplan-Meier analysis revealed distinctly elevated mortality in patients with high plasma MIF-2 levels.ConclusionsMIF-2 levels are elevated in critically ill patients and linked to parameters of organ damage, supporting its value as a potential tool for the assessment of prognosis in critical illness.Copyright © 2017 Elsevier Inc. All rights reserved.

30 keywords...

hide…